Document is current
Any future updates will be listed below
-
Authors
Shadman, Mazyar https://orcid.org/0000-0002-3365-6562
Maloney, David G.
Storer, Barry
Sandmaier, Brenda M.
Chauncey, Thomas R.
Smedegaard Andersen, Niels
Niederwieser, Dietger https://orcid.org/0000-0002-4737-1103
Shizuru, Judith https://orcid.org/0000-0003-3246-4726
Bruno, Benedetto
Pulsipher, Michael A.
Maziarz, Richard T.
Agura, Edward D.
Hari, Parameswaran
Langston, Amelia A.
Maris, Michael B.
McSweeney, Peter A.
Storb, Rainer
Sorror, Mohamed L. https://orcid.org/0000-0001-5260-1981
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R00 HL088021)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01 CA078902, P01 CA018029, P30 CA015704)
- License Information
-
More Information
Article History
Received: 23 January 2019
Revised: 18 July 2019
Accepted: 25 July 2019
First Online: 3 September 2019
Compliance with ethical standards
:
: MS provided consultancy for Abbvie, Genentech, Astra Zeneca and Sound Biologics; has been on the advisory board for Abbvie, Genentech, Pharmacyclics, Astra Zeneca, ADC Therapeutics, Atara, and Verastem; and receives research funding from Mustang Biopharma, Pharmacyclics, Gilead, Genentech, TG Therapeutics, Bigene, Celgene, Acerta, Emergent, Sunesis and Merck. Otherwise, the authors declare that they have no conflict of interest.
